Skip to content

Core Scientific

US · CORZ #2073 by market cap Listed 2024
11.33 -2.03 -15.19%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:02

Valuation each multiple against its own 5-year range

P/B ratio -4.28 In line with history 54th percentile
5-year average -5.37
P/E ratio -44.00 Cheap vs history 7th percentile
5-year average -10.37 · forward 29.66
P/S ratio 7.90 In line with history 45th percentile
5-year average 10.03 · forward 4.14 · #130 of 176 in Software - Infrastructure

Vs. peers Software - Infrastructure

Company Market cap P/E (TTM) P/B Div yield
Core Scientific (CORZ) 3.65B -34.33 -3.34 0.00%
Microsoft (MSFT) 3.60T 25.30 7.65 0.75%
Palantir (PLTR) 345.74B 101.05 30.79 0.00%
Oracle (ORCL) 305.97B 15.86 4.95 1.98%
Palo Alto Networks (PANW) 281.87B 686.64 9.83 0.00%
CrowdStrike (CRWD) 234.93B 6,037.89 46.05 0.00%

Other StockVane-tracked companies in the same industry.

Morningstar

★★★☆☆ Fair value16.53 Economic moatNone UncertaintyHigh

Trading 45.9% below Morningstar's fair value estimate.

Fair value

Core Scientific Inc earns a 3-star quantitative star rating, indicating our belief that this share class is a balanced choice, but prudent investors should consider looking elsewhere. The stock currently trades at a 12% discount to our quantitative fair value estimate of $16.53 per share; however, caution is warranted due to this estimate's high uncertainty rating.

The firm's liquidity bolsters our valuation estimate. Adequate liquidity allows a company to meet short-term obligations, enhancing financial stability and reducing distress risk. Reflecting the firm's liquidity is its median trading volume over the past 60 days, which falls in the top 10% compared with peers globally. Trading volumes are high on shares, which may indicate increased institutional interest in stock ownership. We believe this is a sign that shares could be cheap.

Alternatively, the company's lack of profitability is potentially concerning. Companies with low profitability are often less resilient in recessions and are likely to generate weaker future cash flows for shareholders. The firm's earnings yield of 0.4%, a core component of profitability, falls in the bottom 30% compared with peers globally. The earnings generated by the company relative to its share price is concerning, which, despite our favorable price/fair value ratio, is a negative attribute.

In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has outperformed the broader universe over the past year. This outperformance bodes well for future returns in light of other contributors to our model.

Economic moat

This company lacks a competitive advantage, receiving a quantitative economic moat rating of none. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.

By Quantitative Equity Report

Quote time 2026-11-20 20:02:35 · For reference only, not investment advice and not tailored to your situation.

Core Scientific discussion 0 comments

Add a comment